Shenzhen Lihe Biotech Co., Ltd. and Shenzhen Peptide Biotechnology Co., Ltd. have reached a strategic partnership

On July 11, Shenzhen Lihe Biotechnology Co., Ltd. and Shenzhen Peptide Sheng Biotechnology Co., Ltd. signed an agreement and reached a strategic cooperation relationship. The two parties will integrate resources to jointly promote the construction of the world's first entity peptide library application development that combines peptide structural diversity and sequence diversity, and further promote the discovery and development of peptide innovative drugs. Liu Xiaoyang, strategic consultant of Shenzhen Peptide Sheng Biotechnology Co., Ltd., Li Tianji, vice president and chief financial officer, Wang Yirong, head of BD, Li Xuanqing, director of the General Office, Zeng Lingxi, general manager of Shenzhen Lihe Biotechnology Co., Ltd., and Yang Ti, senior investment manager of Shenzhen Lihe Venture Capital Co., Ltd., attended the signing ceremony.

Shenzhen Peptide Sheng Biotechnology Co., Ltd. was established in October 2022 by Dr. Wang Zhuyin, a serial successful entrepreneurial scientist. The company has built the world's first entity peptide library that combines peptide structural diversity and sequence diversity, and has built a full-process peptide drug discovery technology platform around the peptide library. At present, the company has reached cooperation with institutions and enterprises such as Peptide Valley Research Institute, Shaanxi Zhonghong, and Lanzhou University.

Shenzhen Lihe Biotech Co., Ltd. is a technology-based service platform under Lihe Technology that specializes in providing investment and incubation for biopharmaceutical companies. The company aims to build a competitive full-chain biomedical service system, give full play to its experience advantages in the field of scientific and technological achievements transformation and its resource advantages in the field of biomedical, and provide a wide range of third-party R&D, production, sales and other business outsourcing, intellectual property, financing consulting, strategic consulting and other professional value-added services for entrepreneurial teams and projects, and build a competitive full-chain biomedical service system.

At present, the scale of China's peptide drug market has reached 67 billion yuan, and the scale of peptide-containing cosmetics is nearly 10 billion yuan, and the scale continues to expand. The "complex structure peptide library construction technology" created by Peptide Sheng Bio is the world's only most advanced peptide library that integrates peptide structure diversity and sequence diversity. It has discovered and verified in vitro more than 100 targeted transmold peptides, 15+ kinds of medical beauty active peptides, 50+ antibacterial peptides and other active peptides that can be transferred. In the future, the two companies will further empower the field of peptide innovative drugs through joint efforts, and carry out comprehensive and in-depth cooperation in market promotion, investment consulting, and industrial capital collaboration.